Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.

MLA

Fowler, Robert A., et al. “Cost-Effectiveness of Recombinant Human Activated Protein C and the Influence of Severity of Illness in the Treatment of Patients with Severe Sepsis.” Journal of Critical Care, vol. 18, no. 3, Sept. 2003, pp. 181–91. EBSCOhost, https://doi.org/10.1016/j.jcrc.2003.08.009.

APA

Fowler, R. A., Hill-Popper, M., Stasinos, J., Petrou, C., Sanders, G. D., & Garber, A. M. (2003). Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. Journal of Critical Care, 18(3), 181–191. https://doi.org/10.1016/j.jcrc.2003.08.009

Chicago

Fowler, Robert A, Marya Hill-Popper, John Stasinos, Constantia Petrou, Gillian D Sanders, and Alan M Garber. 2003. “Cost-Effectiveness of Recombinant Human Activated Protein C and the Influence of Severity of Illness in the Treatment of Patients with Severe Sepsis.” Journal of Critical Care 18 (3): 181–91. doi:10.1016/j.jcrc.2003.08.009.